Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 9 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Tislelizumab with etoposide and carboplatin or cisplatin for treating small-cell lung cancer	Carboplatin (Paraplatin) , Cisplatin (Platinol) , Etoposide , Tislelizumab (BGB-A317; BGBA-317)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2022	View \| Download
Tislelizumab with chemotherapy for previously untreated advanced oesophageal squamous cell carcinoma	Tislelizumab (BGB-A317; BGBA-317)	Oesophageal squamous cell carcinoma	Gastrointestinal Cancer	2022	View \| Download
Tislelizumab with chemotherapy for previously untreated unresectable or metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma	Chemotherapy , Tislelizumab (BGB-A317; BGBA-317)	Gastric cancer , Gastro-oesophageal junction adenocarcinoma	Gastrointestinal Cancer	2022	View \| Download
Tislelizumab with chemotherapy for previously untreated advanced squamous or non-squamous non-small-cell lung cancer	Tislelizumab (BGB-A317; BGBA-317)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Tislelizumab in combination with Paclitaxel, Cisplatin, and Radiotherapy for Oesophageal cancer	Cisplatin (Platinol) , Paclitaxel (Taxol; paclitaxel albumin) , Tislelizumab (BGB-A317; BGBA-317)	Squamous cell carcinoma (SCC)	Head and Neck Cancer	2022	View \| Download
Tislelizumab in combination with chemotherapy for nasopharyngeal cancer – first line	Cisplatin (Platinol) , Gemcitabine (Gemzar; gemcitabine hydrochloride) , Tislelizumab (BGB-A317; BGBA-317)	Nasopharyngeal cancer	Head and Neck Cancer	2021	View \| Download
Tislelizumab for treating unresectable, previously untreated hepatocellular carcinoma	Tislelizumab (BGB-A317; BGBA-317)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Tislelizumab for oesophageal cancer – second line	Tislelizumab (BGB-A317; BGBA-317)	Oesophageal cancer	Head and Neck Cancer	2021	View \| Download
Tislelizumab for advanced non-small cell lung cancer after platinum based chemotherapy	Tislelizumab (BGB-A317; BGBA-317)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download

About

Devices, Diagnostics & Digital

About

Data Science & AI

Devices, Diagnostics & Digital

Insights (Public/Patient)

Medicines

Medicine Industry's Gateway to NICE

Support for Industry

Outputs & Publications